New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
Highly Regulated (List I)Translated

PRASIVAST

10 MG/Film-coated Tablet/PRAVASTATINE SODIQUE
EL KENDI DU MEDICAMENT
ManufacturerVerified lab

EL KENDI DU MEDICAMENT

Public retail price
607.40DZD
Reference price (TR): 609.90 DZD

Identification

Active ingredient (INN)
PRAVASTATINE SODIQUE
Internal code
06 M 295
Country of Origin
Algeria
Pharmaceutical form
Film-coated Tablet
Prescription List
Highly Regulated (List I)
Packaging
boite de 30
PRASIVAST
Clinical View
Highly Regulated (List I)

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Associated Conditions

History of hepatopathies History of myopathy

History of acquired myopathy due to statin or fibrate Family history of myopathy Significant alcohol consumption KPC > 5 times the normal upper limit Child under 8 years of age Hypothyroidism Hepatic impairment Renal impairment Myasthenia Patient at risk for diabetes Subject over 70 years Extended treatment.

Mechanism of Action

Mechanism of action

Pravastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase, an enzyme acting in the early stages of cholesterol biosynthesis, and produces its hypolipidemitic effect in two ways.

First, because of its reversible and specific competitive inhibition of HMG Co-A reductase, it induces a moderate decrease in intracellular cholesterol synthesis.

This induces an increase in

LDL receptor counts on the surface of cells as well as a catabolism via these receptors and a reinforced clearance of circulating LDL cholesterol.

Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL-cholesterol, precursor of LDL-cholesterol.

In healthy subjects as well as in hypercholesterolemic patients, pravastatin sodium lowers the following lipid parameters: total cholesterol, LDL-cholesterol, apolipoprotein B, VLDL-Cholesterol and triglycerides; HDL-Cholesterol and triglycerides.

Adverse Effects

  • (increase)
  • Myoglobinuria Transaminases (increase)
  • KPC (increase)
  • ALT (increase)
  • Urticaria (Uncommon)
  • Pathology of the scalp (Uncommon)
  • Hair disorder (Uncommon)
  • Rash (Uncommon)
  • Pruritus (Uncommon)
  • Photosensitivity (Rare)
  • Alopecia Lichenoid eruption Fatigue (Uncommon)
  • Sexual disorder (Uncommon)
  • Hepatitis (Very rare)
  • Ictery (Very rare)
  • Liver necrosis (Very rare)
  • Hepatic impairment Hypersensitivity (Very rare)
  • Dermatomyosite (Very rare)
  • Anaphylactic reaction
  • Angioedema Diabetes Vision disorder (Uncommon)
  • Blurty vision Diplopia Feeling dizzy (Uncommon)
  • Insomnia (Uncommon)
  • Sleep disorder (Uncommon)
  • Depression Nightmare Dyspepsia (Uncommon)
  • Pyrosis (Uncommon)
  • Constipation (Uncommon)
  • Nausea (Uncommon)
  • Abdominal pain (Uncommon)
  • Vomiting (Uncommon)
  • Flatulence (Uncommon)
  • Diarrhoea (Uncommon)
  • Pancreatitis (Very rare)
  • Tendinopathy (Uncommon)
  • Polymyositis (Very rare)
  • Myopathy (Very rare)
  • Rhabdomyolysis (Very rare)
  • Myositis (Very rare)
  • Muscle disorder (Very rare)
  • Lupus-like syndrome Muscle loss
  • Muscle pain Strand cut Joint pain Tendinitis Immune-mediated necrotic myopathy Musculoskeletal pain
  • Cramp Muscle weakness Headache (Uncommon)
  • Paraesthesia (Very rare)
  • Polyneuropathy (Very rare)
  • Memory Disorder Myasthenia Myasthenia eye Memory loss Interstitial pneumopathy (Exceptional)
  • Dysuria (Uncommon)
  • Nycturia Abnormal urination frequency Acute renal impairment.

Alternatives